FDA Approved: INCRELEX — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for INCRELEX (mecasermin) filed by Ipsen Biopharmaceuticals, Inc., resulting in labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin-like Growth Factor Deficiency

Drugs mentioned

• INCRELEX (Mecasermin)

Snippet

SUPPL AP for INCRELEX (MECASERMIN)